A Novel Targeting Therapy of Malignant Mesothelioma Using Anti-Podoplanin Antibody
Shinji Abe(Tokushima University), Yasuhiko Nishioka(Tokushima University), Kazuo Minakuchi(Osaka City University), Seiji Yano(Kanazawa University Hospital), Mami Azuma(Tokushima University), Jun Huang(Fujian Normal University), Yoshitaka Sekido(Aichi Cancer Center), Hisatsugu Goto(Tokushima University), Masatoshi Kishuku(Tokushima University Hospital), Mika K. Kaneko(Tohoku University), Yuki Taniguchi(Tokushima University Hospital), Yukinari Kato(Tohoku University), Yoshinori Aono(Tokushima University), Yuta Tsujimoto(Tohoku University), Seidai Sato(Tokushima University), Masaki Hanibuchi(Tokushima University), Soji Kakiuchi(Tokushima Prefectural Central Hospital), Shin-ichi Akiyama(Tokushima University), Kazuyoshi Kawazoe(SHOWA Medical University), Saburo Sone(Io Therapeutics (United States)), Yuki Morita(Tokushima University Hospital)
Cited by 91
Related Papers
Hepatocyte Growth Factor Induces Gefitinib Resistance of Lung Adenocarcinoma with Epidermal Growth Factor Receptor–Activating Mutations
|Cancer Research|2008|642
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
|Cancer Discovery|2018|630
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
|Nature Communications|2019|360